Novartis Boosts Q3 Earnings by 25% Amid Strong Prescription Drug Demand

Novartis reported a 25% increase in net income for Q3, driven by robust demand for prescription drugs, reaffirming its financial outlook amidst rising research costs.

• In Q3, Novartis achieved a 27% increase in operating income, reaching $4.5 billion in constant currencies, fueled by higher revenue and reduced impairments.
• The Swiss drugmakers net income rose by 25%, attributed to strong performance in key prescription medicines within the competitive landscape of the pharmaceutical market.
• Despite increased spending on research and development, Novartis maintained its full-year outlook, highlighting resilience amid pressures from generic drug competition.